A new study by University of Kentucky Markey Cancer Center researchers shows that when therapy-sensitive cancer cells die, they release a "killer peptide" that can eliminate therapy-resistant cells.
John R. van Nagell, Jr. has worked with countless patients, faculty and students, but his lasting legacy will likely be the Ovarian Cancer Screening Program at the Markey Cancer Center.
Dr. John van Nagell spent his career at UK diagnosing and treating patients, and mentoring and teaching young doctors, but his lasting legacy will likely be his research.
Fifteen years ago Douglas Andres and his team produced data that showed mutations in an on-off switch called RIT1 are a novel driver for human lung cancer.
